Related Experiment Videos
[MALT lymphoma producing IgG-kappa type M-protein]
A Sakai1, Y Katayama, A Mizuno
1Department of Hematology and Oncology, Hiroshima University.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 6, 2000
Summary
A 72-year-old woman with autoimmune conditions developed MALT lymphoma. Treatment led to remission, suggesting lymphoma cells produced monoclonal IgG-kappa.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Idiopathic thrombocytopenic purpura (ITP) and autoimmune hepatitis (AIH) are autoimmune disorders.
- Prednisolone and azathioprine are immunosuppressive agents used to manage ITP and AIH.
- Monoclonal gammopathy (IgG-kappa) can be associated with various conditions, including B-cell malignancies.
Observation:
- A 72-year-old woman with ITP and AIH presented with monoclonal gammopathy (IgG-kappa).
- Tumors in the ileum and descending colon were identified.
- Biopsy confirmed marginal zone B-cell lymphoma of the MALT type with a high-grade component.
- Flow cytometry showed neoplastic B cells expressing CD38, CD19, IgG, and kappa, but not CD5 or CD10.
Findings:
- The patient achieved complete remission after three cycles of THP-COP chemotherapy.
- IgG levels normalized post-treatment.
- The findings suggest that the lymphoma cells were the source of the monoclonal IgG-kappa.
Implications:
- This case highlights a potential link between immunosuppressive therapy and MALT lymphoma development.
- Further research is needed to clarify the relationship between immunosuppressive agents and MALT lymphoma pathogenesis.
- Understanding this relationship is crucial for managing patients with autoimmune diseases and concurrent B-cell malignancies.